Device Trial Radar · NCT07669181
Examination of the Role of Human Exoskeletons in Rehabilitation
Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Dec 1, 2017
Primary completion
Dec 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- University of PecsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 25, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background and Rationale: Traumatic spinal cord injury (SCI) affects approximately 12,400 individuals annually in the USA, predominantly impacting healthy young adults aged 20-40 years. Complete SCI above the lumbar region results in paraplegia or tetraplegia, severely compromising quality of life. Wheelchair-dependent lifestyle and immobilization lead to serious secondary complications including osteoporosis, diabetes mellitus, atherosclerosis, pressure ulcers, depression, and pathological fractures. Robotic exoskeletons have emerged as promising rehabilitation tools since the 2000s, enabling independent walking and stair climbing beyond wheelchair use. Study Objectives: This clinical trial investigates the role of ReWalk lower-limb human exoskeleton in rehabilitation by: Integrating exoskeleton-assisted gait training into rehabilitation protocols and comparing functional and physiological outcomes with conventional conservative treatment in SCI-induced paralysis Examining gastrointestinal and urogenital changes Assessing general well-being and patient compliance Methods: This prospective, controlled study enrolls patients with lower limb paralysis following SCI for minimum 6-month rehabilitation. The control group receives traditional physiotherapy and physical rehabilitation only. All procedures comply with Good Clinical Practice principles and applicable regulations. Inclusion criteria (FDA-approved): Complete SCI below T4 with paraparesis/paraplegia; ≥4 months post-injury; adequate arm/shoulder strength for crutch use; appropriate bone density (hip t-score \>-3.5); intact skeletal system with stable spine; ability to stand safely; good general health; height 160-190cm; weight ≤100kg; adequate lower limb range of motion. Exclusion criteria: Severe neurological diseases beyond SCI; significant concurrent illnesses; severe spasticity (Modified Ashworth 4); unstable spine or limbs; heterotopic ossification; significant contractures; psychiatric/cognitive impairment; pregnancy. Training Protocol: The rehabilitation program consists of five phases: Paravertebral and back muscle strengthening (weeks 1-4): Core strengthening exercises focusing on sitting balance, assessed weekly via trunk control measurement scale Standing, sitting, and device donning (weeks 5-6): Learning independent device application and safe standing balance Gait training (weeks 7-8): Mastering independent device control through various stepping patterns Stair training (weeks 9+): Learning stair negotiation after passing final skill test Follow-up phase (6+ months): Maintenance therapy at reduced frequency (3x/week) Assessment Parameters: Baseline assessments include: ASIA Impairment Scale, bone densitometry, Modified Ashworth Scale, Barthel Index, Functional Independence Measure (FIM), VAS pain/fatigue scales, SF-36, Beck's anxiety/depression inventories. Progress evaluations at major milestones include functional tests (10-meter walk, Timed Up-and-Go, Berg Balance, Spinal Cord Independence Measure) and ReWalk skill assessments. Follow-up assessments (6-month minimum) repeat baseline measures focusing on bone density, functional independence, quality of life, and mental health. Expected Outcomes: Improved bone density with exoskeleton training compared to conventional treatment Improved general well-being and better patient compliance This study aims to confirm previous international findings demonstrating superior outcomes with robotic rehabilitation technology regarding spasticity reduction, bone density preservation, body composition improvement, and gastrointestinal/urogenital/mental health enhancement compared to traditional treatment approaches.
Conditions
- Spinal Cord Injury
Interventions
Exoskeleton based gait therapyDevice
Participants with complete SCI below T4 complete a supervised ReWalk lower-limb exoskeleton rehabilitation program. After several weeks of preparatory physiotherapy to improve trunk control, sitting balance, and upper-limb strength, training progresses to independent donning/doffing, sit-to-stand/stand-to-sit and standing balance, then gait acquisition using manufacturer-defined step settings. Progress is monitored with ReWalk skill tests and repeated functional measures (e.g., 10 m walk, TUG). After mastering walking, stair training is introduced. Sessions are initially 5 times/week for 60-90 minutes with medical supervision and two therapists until safe independent use; then therapy continues for at least 6 months with maintenance typically 3 times/week.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Functional independenceTime frame: enrollment, every month +/- 3 days, end of study at 6 months
- Mobility and walking performanceTime frame: enrollment, every month +/- 3 days, end of study at 6 months
- SpasticityTime frame: enrollment, every month +/- 3 days, end of study at 6 months
4 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Neurosurgery
Pécs, Baranya, Hungary
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.